We report a 44-year-old male patient who was diagnosed with scirrhous gastric cancer with peritoneal dissemination using laparoscopy. The patient underwent a non-curative resection with laparoscopic distal subtotal gastrectomy. In addition, we placed a port into the patient's abdomen for intraperitoneal chemotherapy administration. Postoperatively, we administered capecitabine (per os)+ paclitaxel (intraperitoneally) and, after 2 cycles, the oral anticancer agent 5-FU was given. The patient died of peritonitis carcinomatosa 25 months after the operation. The combined therapies contributed to improve the quality of life, specifically oral ingestion, for 2 years.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Endoscopic mucosal resection and open-lid submucosal biopsy for the diagnosis of diffuse infiltrative gastric cancer: a retrospective observational study.
Scand J Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Background And Study Aims: Diffuse infiltrative gastric cancer can be difficult to diagnose owing to a lack of endoscopic features in the superficial mucosa. Moreover, a forceps biopsy may not reveal a pathological diagnosis. We aimed to evaluate the diagnostic yield and safety of endoscopic mucosal resection (EMR) and 'open-lid submucosal biopsy', a technique wherein EMR followed by biopsy of the ulcer floor is performed for a pathological diagnosis.
View Article and Find Full Text PDF[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab].
Gan To Kagaku Ryoho
November 2024
Dept. of Gastroenterology Gastrointestinal Oncology, National Cancer Center Hospital East.
The standard first-line treatment for unresectable advanced or recurrent gastric cancer(GC)and gastroesophageal junction cancer(GEJC)has been a platinum doublet chemotherapy. Trastuzumab with chemotherapy is the standard regimen for HER2-positive GC/GEJC. While, for HER2-negative cases, chemotherapy with or without immune checkpoint inhibitors (ICIs)such as nivolumab or pembrolizumab are regarded as the standard therapy.
View Article and Find Full Text PDFNovel reconstruction using pedicled ileocolic interposition after laparoscopic total gastrectomy: A report of two cases.
Int J Surg Case Rep
December 2024
Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Introduction: Although Roux-en-Y reconstruction using the jejunum is generally performed after laparoscopic total gastrectomy, the postoperative function is inadequate. We designed a novel reconstruction technique using pedicled ileocolic interposition with laparoscopic anastomosis of the esophagus and ileum, and further anastomosis of the colon and duodenum. Two patients were treated with this technique.
View Article and Find Full Text PDFNecessity of splenectomy for antral-type scirrhous gastric cancer.
Eur J Surg Oncol
October 2024
Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- Total gastrectomy with splenic hilar nodal dissection is a common procedure for treating resectable scirrhous gastric cancer (GC), but the necessity of splenectomy specifically for antral-type GC is uncertain.
- A study at the National Cancer Center Hospital analyzed patients with type IV GC from 2000 to 2018, focusing on those who underwent total gastrectomy with splenectomy and achieved successful tumor resections.
- Results showed no metastasis to the splenic hilar nodes in patients with antral-type GC, suggesting that splenectomy may not be needed for this subtype, while it was common in body-type GC cases.
Gastric-Type Expression Signature in Hepatocellular Carcinoma.
Int J Mol Sci
June 2024
Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
It is known that V-set and immunoglobulin domain containing 1 (VSIG1) is a cell-cell adhesion molecule that can serve as an indicator of better survival in patients with gastric cancer. Its interaction with cytoplasmic thyroid transcription factor 1 (TTF-1) has been hypothesized to characterize gastric-type HCC, but its clinical importance is far from understood. As VSIG1 has also been supposed to be involved in the epithelial-mesenchymal transition (EMT) phenomenon, we checked for the first time in the literature the supposed interaction between VSIG1, TTF-1, and Vimentin (VIM) in HCCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!